Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 3/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11492630 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL7924458 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL7186285 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL11827001 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL7278088 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL11202132 | 1.00 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL8949780 | 0.98 | CA1 (0.52) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL5489710 | 0.95 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL5484425 | 0.95 | CA1 (0.50) | CA1FFAR4FFAR1ACE2FDPS | |
| SCHEMBL2529410 | 0.94 | FFAR4 (0.46) | CA1FFAR4FFAR1ACE2FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233402-B2 | Pressure medium oil and method for using said pressure medium oil | IDEMITSU KOSAN CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-20170283730-A1 | PRESSURE MEDIUM OIL AND METHOD FOR USING SAID PRESSURE MEDIUM OIL | IDEMITSU KOSAN CO., LTD. (JP) | 2017-10-05 | — | — | US | disclosed |
| US-5169950-A | Reacting a 2-mercaptobenzothiazole, acarbonyl and a phenol; basic catalyst; polar solvent | CIBA-GEIGY CORPORATION (US) | 1992-12-08 | — | — | US | disclosed |
| US-5116402-A | HERBICIDAL COMPOSITION CONTAINING DIOXOLANE, DIOXANE, OR DIOXEPANE DERIVATIVES AS ANTIDOTE | MAGYAR TUDOMANVOS AKADEMIA KOZPONTI KEMIAI KUTATO INTEZETE NITROKEMIA INARTELENEK FUZFOGYARTELEP (HU) | 1992-05-26 | — | — | US | disclosed |
| US-5097039-A | Coating, lubricants | CIBA-GEIGY CORPORATION (US) | 1992-03-17 | — | — | US | disclosed |
| US-5069805-A | OIL ADDITIVES | CIBA-GEIGY CORPORATION (US) | 1991-12-03 | — | — | US | disclosed |
| US-4894091-A | PROTECTIVE COATINGS, PHOTOSTABILIZERS, HEAT RESISTANCE | CIBA-GEIGY CORPORATION (US) | 1990-01-16 | — | — | US | disclosed |
| US-4401817-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1983-08-30 | — | — | US | disclosed |
| US-4338329-A | COMBATTING RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4316021-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1982-02-16 | — | — | US | disclosed |
| US-4289782-A | PARTICULARLY FOR INHIBITING GROWTH OF RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| US-4243813-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| US-4230868-A | α-Alkyl-α-hydroxybenzyl-substituted 1-sulfonylbenzimidazoles | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4196125-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4174454-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1979-11-13 | — | — | US | disclosed |
| US-4118573-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4118742-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4018790-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283730-A1 | PRESSURE MEDIUM OIL AND METHOD FOR USING SAID PRESSURE MEDIUM OIL | GRN, NUP160, MYB | CA1 3774/4885FFAR4 3726/4885FFAR1 4225/4885 |
| US-10233402-B2 | Pressure medium oil and method for using said pressure medium oil | GRN, NUP160, MYB | CA1 3774/4885FFAR4 3726/4885FFAR1 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.